Search research articles
Contact Us
Filters
Showing results (1-10 of 32) with videos related to
Page
of 4
Sort By:
Journal of Interventional Cardiac Electrophysiology : an International Journal of Arrhythmias and Pacing
|
February 26, 2015
The effect of C-reactive protein reduction with a highly specific antisense oligonucleotide on atrial fibrillation assessed using beat-to-beat pacemaker Holter follow-up
Conn Sugihara, Nick Freemantle, Steven G Hughes, et al.
Arthritis Research & Therapy
|
April 18, 2015
Results of a proof of concept, double-blind, randomized trial of a second generation antisense oligonucleotide targeting high-sensitivity C-reactive protein (hs-CRP) in rheumatoid arthritis
Marshelle S Warren, Steven G Hughes, Walter Singleton, et al.
Nucleic Acid Therapeutics
|
August 12, 2017
Lack of QT Prolongation for 2'-O-Methoxyethyl-Modified Antisense Oligonucleotides Based on Retrospective Exposure/Response Analysis of Ten Phase 1 Dose-Escalation Placebo-Controlled Studies in Healthy Subjects
Rosie Z Yu, Rudy Gunawan, Richard S Geary, et al.
Journal of Clinical Lipidology
|
November 28, 2017
Temporal variability in lipoprotein(a) levels in patients enrolled in the placebo arms of IONIS-APO(a)<sub>Rx</sub> and IONIS-APO(a)-L<sub>Rx</sub> antisense oligonucleotide clinical trials
Santica M Marcovina, Nicholas J Viney, Steven G Hughes, et al.
European Heart Journal
|
July 23, 2019
N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels
Veronica J Alexander, Shuting Xia, Eunju Hurh, et al.
British Journal of Haematology
|
August 19, 2014
A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia
Farrukh T Awan, Peter Hillmen, Andrzej Hellmann, et al.
CNS Drugs
|
August 18, 2019
An Integrated Safety Analysis of Infants and Children with Symptomatic Spinal Muscular Atrophy (SMA) Treated with Nusinersen in Seven Clinical Trials
Basil T Darras, Michelle A Farrar, Eugenio Mercuri, et al.
Nucleic Acid Therapeutics
|
November 30, 2017
The Effects of 2'-O-Methoxyethyl Oligonucleotides on Renal Function in Humans
Stanley T Crooke, Brenda F Baker, Nguyen C Pham, et al.
Journal of the Neurological Sciences
|
September 17, 2018
Kind and distribution of cutaneous sensation loss in hereditary transthyretin amyloidosis with polyneuropathy
Marcus V Pinto, P James B Dyck, Linde E Gove, et al.
Immunobiology
|
February 2, 2025
Inhibiting the alternative pathway of complement by reducing systemic complement factor B: Randomized, double-blind, placebo-controlled phase 1 studies with Sefaxersen
Michael L McCaleb, Steven G Hughes, Tamar R Grossman, et al.
Page
of 4
Search research articles
Search
Showing results (1-10 of 32) with videos related to
Sort By:
Page
of 4
Journal of Interventional Cardiac Electrophysiology : an International Journal of Arrhythmias and Pacing
|
February 26, 2015
The effect of C-reactive protein reduction with a highly specific antisense oligonucleotide on atrial fibrillation assessed using beat-to-beat pacemaker Holter follow-up
Conn Sugihara, Nick Freemantle, Steven G Hughes, et al.
Arthritis Research & Therapy
|
April 18, 2015
Results of a proof of concept, double-blind, randomized trial of a second generation antisense oligonucleotide targeting high-sensitivity C-reactive protein (hs-CRP) in rheumatoid arthritis
Marshelle S Warren, Steven G Hughes, Walter Singleton, et al.
Nucleic Acid Therapeutics
|
August 12, 2017
Lack of QT Prolongation for 2'-O-Methoxyethyl-Modified Antisense Oligonucleotides Based on Retrospective Exposure/Response Analysis of Ten Phase 1 Dose-Escalation Placebo-Controlled Studies in Healthy Subjects
Rosie Z Yu, Rudy Gunawan, Richard S Geary, et al.
Journal of Clinical Lipidology
|
November 28, 2017
Temporal variability in lipoprotein(a) levels in patients enrolled in the placebo arms of IONIS-APO(a)<sub>Rx</sub> and IONIS-APO(a)-L<sub>Rx</sub> antisense oligonucleotide clinical trials
Santica M Marcovina, Nicholas J Viney, Steven G Hughes, et al.
European Heart Journal
|
July 23, 2019
N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels
Veronica J Alexander, Shuting Xia, Eunju Hurh, et al.
British Journal of Haematology
|
August 19, 2014
A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia
Farrukh T Awan, Peter Hillmen, Andrzej Hellmann, et al.
CNS Drugs
|
August 18, 2019
An Integrated Safety Analysis of Infants and Children with Symptomatic Spinal Muscular Atrophy (SMA) Treated with Nusinersen in Seven Clinical Trials
Basil T Darras, Michelle A Farrar, Eugenio Mercuri, et al.
Nucleic Acid Therapeutics
|
November 30, 2017
The Effects of 2'-O-Methoxyethyl Oligonucleotides on Renal Function in Humans
Stanley T Crooke, Brenda F Baker, Nguyen C Pham, et al.
Journal of the Neurological Sciences
|
September 17, 2018
Kind and distribution of cutaneous sensation loss in hereditary transthyretin amyloidosis with polyneuropathy
Marcus V Pinto, P James B Dyck, Linde E Gove, et al.
Immunobiology
|
February 2, 2025
Inhibiting the alternative pathway of complement by reducing systemic complement factor B: Randomized, double-blind, placebo-controlled phase 1 studies with Sefaxersen
Michael L McCaleb, Steven G Hughes, Tamar R Grossman, et al.
Page
of 4